Chiesi USA Appoints Jon Zwinski as General Manager and Chief Executive Officer
December 08, 2020 09:00 ET
|
Chiesi USA, Inc.
Jon Zwinski succeeds Ken McBean as company advances global therapeutic efforts CARY, N.C., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici...
Chiesi USA, Inc. Supports March of Dimes Eastern North Carolina in Observance of Prematurity Awareness Month
November 17, 2020 09:00 ET
|
Chiesi USA, Inc.
CARY, N.C., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), a specialty pharmaceutical company based in Cary, N.C., is proud to once again support March of Dimes in its mission to improve...
Chiesi USA, Inc. Earns Fourth Consecutive Corporate Philanthropy Award by Triangle Business Journal
November 11, 2020 09:00 ET
|
Chiesi USA, Inc.
CARY, N.C., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), a specialty pharmaceutical company based in Cary, N.C., earned the Triangle Business Journal’s 2020 Corporate Philanthropy...
Chiesi USA, Inc. announces FDA approval of Bronchitol® (mannitol) inhalation powder
November 02, 2020 10:26 ET
|
Chiesi USA, Inc.
CARY, N.C., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), received U.S....
Chiesi Global Rare Diseases Launches “Rethink Fabry” Campaign to Bring Important Information to Fabry Disease Community and Support Patients and Caregivers
October 13, 2020 08:00 ET
|
Chiesi USA, Inc.
Disease education program aims to help patients, caregivers and families affected by Fabry disease to make informed healthcare decisions Program includes new resources for healthcare professionals to...
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
October 02, 2020 08:00 ET
|
Chiesi USA, Inc.
BOSTON and CARMIEL, Israel, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare group (Chiesi...
Chiesi USA, Inc. Earns 2020 Life Sciences Award by Triangle Business Journal
August 24, 2020 09:00 ET
|
Chiesi USA, Inc.
CARY, N.C., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), a specialty pharmaceutical company based in Cary, North Carolina, was named Company of the Year by the Triangle Business...
Chiesi publishes its annual report: Group generates almost €2 billion and obtains B Corp certification in 2019
July 16, 2020 08:30 ET
|
Chiesi USA, Inc.
Chiesi Group reports €1,992.81 million in revenue, around 6,000 employees, an 11% reduction in CO2 emissions and more than a fourfold increase in renewable energy consumption.The report, which is...
Chiesi Group Receives FDA Approval for Ferriprox® (deferiprone) twice-a-day tablets
May 21, 2020 10:47 ET
|
Chiesi USA, Inc.
BOSTON, May 21, 2020 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), today...
Chiesi Global Rare Diseases Recognizes Fabry Disease Awareness Month and Launches “Fabry Focus on Health” Educational Series to Support Patients and Caregivers During COVID-19 Pandemic
April 24, 2020 08:00 ET
|
Chiesi USA, Inc.
Program offers suggestions from leading clinicians and other experts regarding impact of COVID-19 on families affected by Fabry disease BOSTON, April 24, 2020 (GLOBE NEWSWIRE) -- Chiesi Global...